Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Lisa Salvatore

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3864-0719; OpenAlex author ID A5026748433, A5121041252. Sources: ClinicalTrials.gov.

Their work

Papers
18 (first author 2, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
84
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 4 papers · 2024: 4 papers, 1 trial · 2025: 4 papers · 2026: 3 papers

Papers 18

  1. Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study. Co-author DOI 10.1016/j.esmogo.2025.100276↗
  2. Prognostic impact of Geriatric 8 and comprehensive geriatric assessment in older patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jgo.2025.102782↗
  3. Response to letter to the Editor: Geriatric assessment and sarcopenia in pancreatic cancer: Toward personalized treatment beyond chronological age. First author DOI 10.1016/j.jgo.2026.102890↗
  4. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  5. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemothe… Co-author DOI 10.1016/j.dld.2025.11.007↗
  6. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  7. Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic… Co-author DOI 10.1186/s13046-024-03238-x↗
  8. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2024.114226↗
  9. Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-… Last author DOI 10.1016/s1470-2045(24)00511-4↗
  10. Weighted gene co-expression network analysis reveals key stromal prognostic markers in pancreatic cancer. Co-author DOI 10.1038/s41598-024-82563-9↗
  11. Combined Nabpaclitaxel pressurized intraPeritoneal aerosol chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal m… Co-author DOI 10.1515/pp-2024-0010↗
  12. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  13. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  14. The role of the multidisciplinary tumor board (MDTB) in the assessment of pancreatic cancer diagnosis and resectability: A tertiary referral center experience. Co-author DOI 10.3389/fsurg.2023.1119557↗
  15. Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies. Co-author DOI 10.3390/nu15030727↗
  16. Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis. First author DOI 10.1159/000525945↗
  17. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  18. Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. Co-author DOI 10.1038/s41430-018-0155-5↗

Trials 1

  1. The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract Principal investigator NCT06728358↗

Closest collaborators

The 25 strongest of 84 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giampaolo Tortora · 16 shared papers, 2018–2026 · strength 3.01
  2. Giovanni Trovato · 4 shared papers, 2024–2026 · strength 1.14
  3. Monica Niger · 7 shared papers, 2021–2026 · strength 1.06
  4. Mario Scartozzi · 4 shared papers, 2023–2026 · strength 0.68
  5. Ilario Giovanni Rapposelli · 5 shared papers, 2021–2025 · strength 0.67
  6. Marina Macchini · 5 shared papers, 2021–2025 · strength 0.66
  7. Giulia Orsi · 5 shared papers, 2021–2025 · strength 0.66
  8. Guido Giordano · 5 shared papers, 2021–2025 · strength 0.66
  9. Michele Reni · 5 shared papers, 2021–2025 · strength 0.66
  10. Stefano Cascinu · 5 shared papers, 2021–2025 · strength 0.66
  11. Sergio Alfieri · 4 shared papers, 2022–2024 · strength 0.64
  12. Carmine Carbone · 3 shared papers, 2024–2025 · strength 0.62
  13. Letizia Procaccio · 4 shared papers, 2023–2025 · strength 0.61
  14. Elisa Giommoni · 4 shared papers, 2023–2025 · strength 0.58
  15. Silvia Bozzarelli · 4 shared papers, 2023–2025 · strength 0.58
  16. Caterina Vivaldi · 3 shared papers, 2025–2026 · strength 0.55
  17. Michèle Milella · 4 shared papers, 2021–2025 · strength 0.51
  18. Marta Chiaravalli · 3 shared papers, 2024–2025 · strength 0.50
  19. Ingrid Garajová · 3 shared papers, 2023–2025 · strength 0.44
  20. Giuseppe Quero · 3 shared papers, 2022–2023 · strength 0.44
  21. Antonio Agostini · 2 shared papers, 2024–2025 · strength 0.42
  22. Andrea Pretta · 2 shared papers, 2025–2026 · strength 0.39
  23. Maria Grazia Rodriquenz · 3 shared papers, 2021–2025 · strength 0.37
  24. Mariacristina Di Marco · 3 shared papers, 2021–2025 · strength 0.37
  25. Federico Nichetti · 2 shared papers, 2025–2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.